Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Globe and Mail, The (Toronto, Canada)]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Globe and Mail, The
This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero. The transaction involved the exercise and immediate sale of options; Bernstein no longer holds any direct shares of Common Stock following this transaction. Maze Therapeutics (NASDAQ:MAZE) R&D President and Chief Medical Officer Harold Bernstein reported a sale of 15,000 shares of Common Stock for a total of approximately $442,000 on April 1, 2026, through an exercise of options with immediate disposition, as disclosed in a SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value ~$442,000 Post-transaction shares (direct) Post-transaction value (direct ownership) Transaction value based on SEC Form 4 weighted average purchase price ($29.46). Key questions How does this transaction affect Harold Bernstein's exposure to Maze Therapeutics? Bernstein's direct Common Stock holdings were red
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Yahoo! Finance]Yahoo! Finance
- Maze Therapeutics (MAZE) had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an "overweight" rating on the stock.MarketBeat
- Maze Therapeutics (MAZE) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" MarketBeat
- MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.MarketBeat
MAZE
Earnings
- 3/25/26 - Beat
MAZE
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/1/26 - Form 4
- MAZE's page on the SEC website